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Xylopia laevigata (Annonaceae) is a medicinal plant used in folk medicine to treat pain and inflammation. Thus, we investigated
the possible antioxidant, antinociceptive, and anti-inflammatory effects of X. laevigata leaf essential oil (EOX) in animal models.
Our EOX sample showed the presence of 𝛾-muurolene (17.78%), 𝛿-cadinene (12.23%), bicyclogermacrene (7.77%), and 𝛼-copaene
(7.17%) as main compounds. EOX presented a strong antioxidant potential according to the DPPH, TBARS, and nitrite production
tests. Additionally, pretreatment with EOX, in mice, also significantly produced (𝑃 < 0.05 or 𝑃 < 0.001) antinociceptive effect by
reduction of nociceptive behavior (in formalin and writhing tests). The EOX showed c-Fos label in the olfactory bulb, piriform
cortex, and periaqueductal gray. Acute administration of EOX exhibited a significant (𝑃 < 0.01 or 𝑃 < 0.001) anti-inflammatory
profile in the carrageenan-induced peritonitis and by the carrageenan-induced hindpaw edema tests in mice. Our results provide
evidence for the use of X. laevigata by traditional medicine practitioners in the management of pain and inflammatory disorders.
1. Introduction
The Annonaceae is a large family of tropical and subtropical
trees and shrubs, comprising about 135 genera and more
than 2500 species [1, 2]. This family is known for its edible
fruits and the medicinal properties of many of its species
[3, 4]. Previous chemical and pharmacological investigations
on some species of this family have indicated the presence
of important bioactive compounds exhibiting various phar-
macological activities, including antidiarrhoeal, analgesic,
antimicrobial, insecticidal, antiparasitic, and antitumor prop-
erties [5–8].
In the Brazilian Northeast, Xylopia laevigata (Mart.) R.E.
Fries (Annonaceae) is commonly called “meiu´” or “pinda´ıba,”
and it is a plant (leaves and flowers) used popularly to treat
painful disorders, heart disease, and inflammatory condi-
tions (oral communications received from local woodsmen
known as “mateiros”; data no published). Recently, our group
demonstrated anticancer activity of X. laevigata essential oil
[9]. However, there is little information about X. laevigata’s
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biological properties. To the best of our knowledge, this is the
first scientific report on the pharmacological properties of the
X. laevigata species using the antioxidant, analgesic, and anti-
inflammatory approaches.
As part of our continuous interest in the Brazilian North-
east’s native plants and to support the use of this plant in folk
medicine, we investigated the antioxidant, antinociceptive,
and anti-inflammatory profiles of the essential oil obtained
from the leaves of X. laevigata (EOX) through experimental
protocols. Additionally, we investigate the effects of EOX on
the central nervous system (CNS) areas by immunofluores-
cence technique to c-Fos.
2. Materials and Methods
2.1. Chemicals. Acetic acid, Tween 80, formalin, trichlo-
roacetic acid, indomethacin, glycine, luminol (5-amino-2,3-
dihydro-1,4-phthalazinedione), TBARS (thiobarbituric acid
reactive species), phosphate buffer, sodium nitroprusside,
and Griess reagent were purchased from Sigma (USA). Mor-
phine and naloxone were purchased from Crista´lia (Brazil).
2.2. Plant Material. The leaves of X. laevigata were collected
in March 2010 in the “Serra de Itabaiana,” between the cities
of Itabaiana and Areia Branca, Sergipe State, Brazil, at the
coordinates [S 10∘44󸀠53󸀠󸀠 W 037∘20󸀠21󸀠󸀠]. The species were
identified by Dr. Ana Paula do Nascimento Prata, plant
taxonomist from the Department of Biology (DBI) of the
Federal University of Sergipe (UFS). A voucher specimen,
number ASE-15440, was deposited at the Herbarium ASE of
theUFS (ASE/UFS).The leaves were obtained fromflowering
species.
2.3. Hydrodistillation of the Essential Oil. The essential oil
from dried leaves (for 24 h) of X. laevigata (200 g) was
obtained by hydrodistillation for 3 h using a Clevenger-type
apparatus. The essential oil (EOX) was dried over anhydrous
sodium sulphate, and the percentage content was calculated
on the basis of the dry weight of plant material. The essential
oils were stored in a freezer until analysis. The hydrodistilla-
tion of the essential oil was performed in triplicate.
2.4. GC Analysis. GC analyses were carried out using a Shi-
madzu GC-17A fitted with a flame ionization detector (FID)
and an electronic integrator. Separation of the compounds
was achieved employing a ZB-5MS fused capillary column
(30m × 0.25mm × 0.25 𝜇m film thickness) coated with 5%-
phenyl-arylene-95%-methylpolysiloxane. Helium was the
carrier gas at 1.2mL⋅min−1 flow rate.The column temperature
program was 50∘C/2min, followed by a rate of 4∘C/min to
200∘C, then a rate of 15∘C/min to 300∘C, and then a rate
of 300∘C/15min [9]. The injector and detector temperatures
were 250∘C and 280∘C, respectively. Samples (0.5 𝜇L in
CH
2
Cl
2
) were injected with a 1 : 100 split ratio. Retention
indices were generated with a standard solution of n-alkanes
(C9–C18). Peak areas and retention times were measured by
an electronic integrator. The relative amounts of individual
compounds were computed fromGC peak areas without FID
response factor correction.
2.5. GC/MS Analysis. GC/MS analyses were performed on a
Shimadzu QP5050A GC/MS system equipped with an AOC-
20i autoinjector. A J&W Scientific DB-5MS (coated with
5%-phenyl-95%-methylpolysiloxane) fused capillary column
(30m × 0.25mm × 0.25 𝜇m film thickness) was used as the
stationary phase. MS were taken at 70 eV with scan interval
of 0.5 s and fragments from 40–500Da.The other conditions
were similar to the GC analysis [12].
2.6. Identification of Constituents. EOX components were
identified by comparing the retention times of the GC peaks
with standard compounds run under identical conditions, by
comparison of retention indices [10] andMSwith those in the
literature [11] and by comparison of MS with those stored in
the NIST and Wiley libraries.
2.7. Antioxidant Tests
2.7.1. Free Radical Scavenging Activity. The free radical scav-
enging activity of the extract was determined based on
its ability to scavenge the stable DPPH free radical. The
experimental protocol was done according to the method
described by Leite et al. [13]. Stock solution (10mg/mL) of
the EOX was prepared in EtOH, and serial dilutions were
carried out to obtain concentrations of 1, 5, 10, 15, 20, 25,
30, and 35 𝜇g/mL. Diluted solutions (2mL) were added to
2mL of a 0.004% EtOH solution of DPPH, mixed, and
allowed to stand for 30min for the reaction to occur. The
equation of the concentration × absorbance calibration curve
for the DPPH radical was 𝐶 = 110.547 − 0.02804𝐴, where
𝐶 is the concentration of the DPPH radical in medium
and 𝐴 is the absorbance at 515 nm. The correlation coeffi-
cient was R = 0.9983. The percentage of remaining DPPH
(%DPPHREM) was calculated according to Brand-Williams
et al. [14] as follows: %DPPHREM = [DPPH]T/[DPPH]T0
× 100, where 𝑇 is the time when absorbance was deter-
mined (1–60min) and T0 is the zero time. The amount of
antioxidant necessary to decrease the initial concentration
of DPPH radical by 50% (IC50) was calculated by plotting
the percentage of DPPHREM at time of 60min against
various concentrations of EOX.The results were expressed as
𝜇g antioxidant/mL DPPH ± standard deviation. Butylated-
hydroxytoluene (BHT) was used as the positive control.
2.7.2. TBARS Assay. TBARS assay was employed to quantify
lipid peroxidation [15], and an adapted TBARS method was
used to measure the antioxidant capacity of EOX using
egg yolk homogenate as lipid-rich substrate [16]. Briefly,
egg yolk was homogenized (1% w/v) in 20mM phosphate
buffer (pH 7.4), and after that, 1mL of the homogenate was
sonicated and then homogenized with 0.1mL of EOX at
different concentrations. Lipid peroxidation was induced by
addition of 0.1mL AAPH solution (0.12M). The vehicle used
to dilute the EOX (DMSO 10%) was used as the control
group. Reactions were carried out for 30min at 37∘C. After
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cooling, samples (0.5mL) were centrifuged with 0.5mL of
trichloroacetic acid (15%) at 1200×g for 10min. An aliquot
of 0.5mL from supernatant was mixed with 0.5mL TBA
(0.67%) and heated at 95∘C for 30min. After cooling, sample
absorbance was measured using a spectrophotometer at
532 nm. The results were expressed as percentage of TBARS
formed by AAPH alone (induced control).
2.7.3. Scavenging Activity of Nitric Oxide (NO). Nitric oxide
was generated from spontaneous decomposition of sodium
nitroprusside in 20mM phosphate buffer (pH 7.4). Once
generated, NO interacts with oxygen to produce nitrite
ions, which were measured by the Griess reaction [17]. The
reaction mixture (1mL) containing 10mM sodium nitro-
prusside (SNP) in phosphate buffer and EOX, at different
concentrations, was incubated at 37∘C for 1 h. A 0.5mL
aliquot was taken and homogenized with 0.5mL Griess
reagent. The absorbance of chromophore was measured at
540 nm. Percent inhibition of the nitric oxide generated was
measured by comparing the absorbance values of negative
controls (only 10mM sodium nitroprusside and vehicle) and
assay preparations. Results were expressed as percentage of
nitrite formed by SNP alone [16].
2.8. Analgesic and Anti-Inflammatory Protocols
2.8.1. Animals. Male Swiss albino mice weighing 28–34 g
were housed at 22 ± 2∘C under a 12 h light/12 h dark cycle
(lights on at 6:00 a.m.), with access to food and water ad
libitum.The animals were acclimatized for 12 h before testing,
and they were used only once throughout the experiments.
The experiments were performed according to the Animal
Care and Use Committee at the Federal University of Sergipe
(CEPA/UFSN∘ 16/11), and we followed the current guidelines
for the care of laboratory animals and the ethical guidelines
for investigations of experimental pain in conscious animals
[18]. The number of animals (𝑛 = 6–8, per group) and inten-
sities of noxious stimuli used were theminimumnecessary to
demonstrate the consistent effects of the drug treatments.
2.8.2. Acetic Acid-Induced Nociception. The abdominal
constrictions were induced according to the procedures
described previously [19]. The animals were pretreated
with EOX at the doses of 12.5, 25, or 50mg/kg (i.p.) 1 h
before injection with acetic acid (0.1mL/10 g). The control
animals (𝑛 = 8, per group) received a similar volume
of vehicle (saline + 2 drops of Tween 80 0.2%), and the
standard group was treated with morphine (MOR, 3mg/kg,
i.p.). After the algogen administration, pairs of mice were
placed in separate boxes, and the number of abdominal
constrictions was cumulatively counted over a period
of 15min. Antinociceptive activity was expressed as the
reduction in the number of constrictions in mice pretreated
with EOX [16]. Possible antagonism by the EOX or MOR
antinociceptive effect was evaluated by pretreatment with
naloxone (NAL, 1.5mg/kg, i.p.), a nonselective opioid
antagonist.
2.8.3. Formalin-Induced Pain. We used the Hunskaar and
Hole [20] procedure with slight modifications. Nociception
was induced by injecting 0.02mL of 1% formalin in distilled
water into the subplantar of the right hindpaw. Mice (𝑛 =
8, per group) were given EOX (12.5, 25, or 50mg/kg, i.p.),
morphine (MOR, 3mg/kg), or vehicle 1 h prior to injecting
formalin. These mice were individually placed in an acrylic
box (25 cm × 15 cm × 15 cm) with mirrors placed on three
sides and under the box to enable unhindered observation of
the formalin injected paw for assessing the pain reaction time.
The time spent paw licking was counted from 0 to 5min (first
phase) and from 15 to 30min (second phase). These phases
represented neurogenic and inflammatory pain responses,
respectively [21].
2.8.4. Rotarod Test. To investigate if the treatments with EOX
influenced themotor activity of the animals and consequently
impaired the assessment of the nociceptive behavior in the
experimental models, we evaluated the motor activity of the
animals [22]. The mice able to remain on the rotarod appa-
ratus (AVS, Brazil) longer than 180 s (7 rpm) were selected
24 h before the test. Then, the selected animals were divided
into five groups (𝑛 = 6, per group) and treated i.p. with
vehicle (control), EOX (12.5, 25, or 50mg/kg), or diazepam
(DZP, 3mg/kg). One hour later, each animal was tested on
the rotarod apparatus, and the time (s) they remained on the
bar for up to 180 s was recorded after 60min.
2.8.5. Leukocyte Migration to the Peritoneal Cavity Test.
Leukocytemigrationwas induced by injection of carrageenan
(500𝜇g/cavity, i.p., 500𝜇L) into the peritoneal cavity of mice
(𝑛 = 6, per group) 1 h after administration of EOX (12.5,
25, or 50mg/kg, i.p.) or indomethacin (INDO, 10mg/kg,
i.p.) by modification of the technique previously described
by [23]. The mice were euthanized by cervical dislocation
4 h after carrageenan injection. Shortly afterwards, phosphate
buffered saline (PBS) containing EDTA (1mM, i.p., 10mL)
was injected. Immediately, a brief massage was done for
further fluid collection, which was centrifuged (2000 rpm,
5min) at room temperature. The supernatant was disposed
and 1mL of PBS was introduced to the precipitate. An
aliquot of 10 𝜇L from this suspension was dissolved in
200𝜇L Turk solution, and the total cells were counted in
a Neubauer chamber, under optical microscopy. The results
were expressed as the number of leukocytes/mL. The per-
centage of leukocyte inhibition = (1 − 𝑇/𝐶) × 100, where T
represents the treated group leukocyte count andC represents
the control group leukocyte count.
2.8.6. Carrageenan-Induced Mice Paw Edema. This test was
used to determine the anti-inflammatory action of EOX by
the method described by [24], with alterations. Groups of 8
mice received, by the intraperitoneal route, either 10mg/kg
INDO (reference drug), EOX (12.5, 25 or 50mg/kg), or
vehicle (saline + 2 drops of Tween 80 0.2%). One hour before
this, they had been given a subplantar injection of 0.1mL/paw
of carrageenan solution (200mg/kg) suspended in distilled
water into the right hindpaw. The mouse paw volume up
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to the ankle joint was measured using a plethysmometer
(LE 7500, PanLab, Spain) at 0 (just before) and 3 h after the
injection of carrageenan. The increase in paw edema volume
was considered as the difference between 0 and 3 h.
2.8.7. Immunofluorescence. Ninety minutes after the EOX
intraperitoneal injections at doses 12.5, 25, and 50mg/Kg the
animals (𝑛 = 4 per group) were anesthetized (ketamine
100mg/Kg and xylazine 10mg/Kg) and submitted to tran-
scardial perfusion with phosphate buffer (0.01M) saline
isotonic (PBS) followed by formalin 10% buffered 0.1M (pH
7.4) and brains were collected, cryoprotected, and stored at
−80∘C with Tissue-Tek O.C.T. (Sakura-USA) for immunoflu-
orescence processing to c-Fos.
Frozen serial transverse sections of 20𝜇m containing
the olfactory bulb, piriform cortex, and periaqueductal gray
were collected on gelatinized glass slides. The tissue sections
were stored at –80∘C until use. The sections were washed
with PBS 3 times for 5 minutes and incubated with 0.1M
glycine in PBS for 10 minutes. Nonspecific protein binding
was blocked by incubation of the sections for 30 minutes
in a solution containing 1% bovine serum albumin (BSA).
After that, the sections were incubated overnight with rabbit
polyclonal c-Fos antibody (sc52 from Santa Cruz Biotech.,
USA) as primary antibodies. Afterwards, the sections were
incubated for one hour with donkey polyclonal antibody to
rabbit IgG conjugatedwithAlexa Fluor 594 as secondary anti-
bodies (Life Technologies, USA).The cover slip wasmounted
with Fluoromount G (Electron Microscopy Sciences, USA).
As an immunofluorescence control for nonspecific labeling
(negative control; (data no shown)), brain sections were
incubated without primary antibody. As positive control
(data no shown), it was processed for immunofluorescence
brain sections containing the supraoptic nucleus from an
animal previously submitted to osmotic stimulus (2mL/100 g
of animal weight) with hypertonic saline (0.5M) instead of
EOX. After each stage, slides were washed with PBS 3 times
for 5 minutes.
2.9. Acquisition and Analyses of Images. An average num-
ber of the c-Fos positive cells of the fifteen pictures from
a piece studied nucleus (olfactory bulb, piriform cortex,
and periaqueductal gray) acquired (Axioskop 2 plus, Carl
Zeiss, Germany) for each animal were calculated. Four
animals were used to each tested dose of EOX. The olfac-
tory bulb, piriform cortex, and periaqueductal gray were
classified in agreement with the description of Paxinos
and Watson Atlas (1997). Neurons were counted of the
whole studied nucleus by Image J (National Institute of
Health) using a plugin (written by authors described at
http://www.lb.ufs.br/lcb/index.php/turorial-for-imagej) that
use the same level of label intensity to select and count the
c-Fos positive cells.
2.10. Statistical Analysis. The data obtained were evaluated
by analysis of variance (ANOVA), either one- or two-way,
followed by Tukey’s or Fisher’s tests. In all cases, differences
were considered significant if 𝑃 < 0.05. All statistical
analyses were done using GraphPad Prism 3.02 (GraphPad
Prism Software Inc., SanDiego, CA, USA). Percent inhibition
of edema volume between treated and control group was
calculated using the following formula: Inhibition % = 100 ⋅
(Vc−Vt)/Vc, where Vc andVt representmean increase in paw
volume in control and treated groups, respectively.
3. Results
3.1. Chemical Composition. Hydrodistillation of the leaves of
X. laevigata gave a light-yellowish crude essential oil (EOX),
with a yield of 1.58% (w/w), in relation to the dryweight of the
plant material. As shown in Table 1, it was possible to identify
36 compounds. The EOX was constituted predominantly by
sesquiterpene compounds at 91.30%. The major compounds
identified were 𝛾-muurolene (17.78%), 𝛿-cadinene (12.23%),
bicyclogermacrene (7.77%), 𝛼-copaene (7.17%), germacrene
D (6.54%), (E)-caryophyllene (5.87%), 𝛾-cadinene (4.72%),
aromadendrene (4.66%), and 𝛾-amorphene (4.39%).
In addition to the major constituents, limonene (3.36%),
𝛼-cubebene (3.04%), germacrene B (2.86%), spathulenol
(2.29%), 𝛽-copaene (1.86%), 𝛼-ylangene (1.26%), 𝛼-pinene
(1.25%), 𝛽-cubebene (1.20%), and 𝛼-muurolol (1.11%) have
been reported in the essential oils of several other species of
Xylopia (Maia et al., 2005), indicating that this species is a
typical member of the Annonaceae family.
The amount of DPPH radical that reacted with EOX
(30 𝜇g/mL, 30min) was 98.15% (Table 2). The essential
oil presented a response similar to the positive control,
butylated-hydroxytoluene (BHT) (30𝜇g/mL, 30min).
To assess the antioxidant potential of EOX, we tested its
ability to prevent oxidative damage to lipids induced by a
free radical source in vitro (AAPH).Quantification byTBARS
demonstrated that EOX exerts a significant (𝑃 < 0.05 or 𝑃 <
0.001) antioxidant effect against peroxyl radicals generated by
AAPH, protecting lipids from oxidation in a dose-dependent
fashion (Figure 1).
To determine the ability of EOX to act as a reactive
nitrogen species (RNS) scavenger, we evaluated the NO-
scavenging activity by incubating EOX with sodium nitro-
prusside (SNP), a chemical inducer of NO production. EOX
at 10 𝜇g/mL, 100 𝜇g/mL, and 1mg/mL showed a significant
NO-scavenging activity with 𝑃 < 0.01 (Figure 2).
As shown in Table 3, EOX at the doses of 12.5, 25, or
50mg/kg (i.p.) significantly inhibited (𝑃 < 0.01 or 𝑃 <
0.001) the acetic acid-induced writhings and two phases of
formalin-induced nociception in mice. Pretreatment with
naloxone did not reverse the effect of EOX (50mg/kg, i.p.) but
antagonized the antinociceptive effect of MOR on the acid-
induced writhing response.
In the rotarod test, EOX treated mice did not show any
significant motor performance alterations with the doses of
12.5, 25, or 50mg/kg (data no shown). As might be expected,
diazepam (3mg/kg, i.p., standard drug) significantly reduced
the time of treated animals on the rotarod apparatus when
compared with the control group.
Carrageenan (500 𝜇g/cavity) induced leukocyte migra-
tion to the peritoneal cavity 4 h after stimulus. Table 4
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Table 1: Essential oil composition from the leaves of X. laevigata.
Compound RIa RIb X. laevigata leaf oil %
1 𝛼-Pinene 931 932 1.25
2 𝛽-Pinene 975 974 0.40
3 Limonene 1027 1024 3.36
4 (Z)-𝛽-Ocimene 1034 1032 0.38
5 𝛿-Elemene 1333 1335 0.65
6 𝛼-Cubebene 1345 1345 3.04
7 𝛼-Ylangene 1367 1373 1.26
8 𝛼-Copaene 1374 1374 7.17
9 𝛽-Bourbonene 1381 1387 0.51
10 𝛽-Cubebene 1386 1387 1.20
11 (E)-Caryophyllene 1417 1417 5.87
12 𝛽-Copaene 1427 1430 1.86
13 Aromadendrene 1436 1439 4.66
14 Trans-Muurola-3,5-diene 1447 1451 0.33
15 𝛼-Humulene 1453 1452 0.83
16 Alloaromadendrene 1458 1458 0.25
17 Cis-Cadina-1(6),4-diene 1460 1461 0.17
18 Trans-Cadina-1(6),4-diene 1469 1475 Tr
19 𝛾-Muurolene 1474 1478 17.78
20 Germacrene D 1480 1484 6.54
21 𝛿-Selinene 1485 1492 0.17
22 𝛾-Amorphene 1490 1495 4.39
23 Bicyclogermacrene 1494 1500 7.77
24 𝛼-Muurolene 1496 1500 Tr
25 𝛿-Amorphene 1503 1511 0.13
26 𝛾-Cadinene 1511 1513 4.72
27 𝛿-Cadinene 1516 1522 12.23
28 Trans-Cadina-1,4-diene 1530 1533 0.33
29 𝛼-Cadinene 1534 1537 1.09
30 𝛼-Calacorene 1539 1544 0.63
31 Germacrene B 1557 1559 2.86
32 𝛽-Calacorene 1560 1564 Tr
33 Spathulenol 1575 1577 2.29
34 Caryophyllene oxide 1580 1582 0.65
35 𝛼-Muurolol 1642 1644 1.11
36 𝛿-Cadinol 1653 1649 0.81
Monoterpenes 5.39
Sesquiterpenes 91.30
Total identified 96.69
RIa (calc.), retention indices on DB-5MS column calculated according to van Den Dool and Dec. Kratz (1963) [10]. RIb retention indices according to Adams
(2007) [11]. Tr: trace.
Table 2: Radical scavenging activity of X. laevigata leaf essential oil
(EOX) determined by the reduction of DPPH free radical.
Samples IP (%) IC50 (𝜇g/mLDPPH)
EOX 98.15 11.98 ± 0.55∗
BHT 99.26 11.06 ± 0.61∗
𝑛 = 4. ∗IC50 and IP (30 𝜇g/mL) of extracts were calculated at the steady state
(30min).
shows the inhibitory effect of EOX on carrageenan-induced
responses in a dose-dependent manner (33.5, 36.4, and
42.4% at doses of 12.5, 25, and 50mg/kg, resp.; 𝑃 < 0.01
or 𝑃 < 0.001). Additionally, the mean increase in paw
edema volume was about 48.3 ± 2.8mL in the vehicle-treated
control mice. EOX (25 and 50mg/kg, i.p.) significantly (𝑃 <
0.01) reduced the mean paw edema volume at 3 h after
carrageenan injection. The standard drug, indomethacin
(INDO, 10mg/kg, i.p.), showed highly significant (𝑃 <
0.001) anti-inflammatory activity in both inflammatory tests
(Table 4).
In the olfactory bulb and in the piriform cortex (Figure 3
and Table 5) of the animals, the average number of neurons
showing c-Fos was increased by an intraperitoneal injection
of EOX at doses of 25 and 50mg/Kg when compared with
control (vehicle). However, the intraperitoneal injections of
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Figure 1: TBARS in vitro. Lipid extracted from egg yolk was subjected to oxidative damage by incubation with AAPH, and the ability of
different concentrations of EOX to prevent TBARS formationwas analyzed. Controlmeans basal lipid peroxidationwith vehicle alone (DMSO
10%); AAPH alone group is considered as 100% of oxidative damage. Values represent mean ± S.E.M., 𝑛 = 4, experiments in triplicate.
#
𝑃 < 0.001versus control; ∗𝑃 < 0.05 and ∗∗𝑃 < 0.001 different versus AAPH group (system) (ANOVA followed by Tukey’s test).
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Figure 2: NO-scavenging activity. Control means basal NO production of vehicle (DMSO 10%) in the absence of a NO generator source
(without SNP); SNP group reflects nitrite production by sodium nitroprusside alone, considered 100% of NO production. The effect of
different concentrations of EOX against SNP was determined by the Griess method. Values represent mean ± S.E.M., 𝑛 = 4, experiments
in triplicate. #𝑃 < 0.001 versus control; ∗𝑃 < 0.01 different versus SNP (ANOVA followed by Tukey’s test).
EOX at dose of 12.5mg/Kg did not change the average
number of neurons showing c-Fos when compared with
control (vehicle).
In the periaqueductal gray (Figure 3 and Table 5) of the
animals, the average number of neurons showing c-Fos was
increased by an intraperitoneal injection of EOX at doses of
12.5, 25, and 50mg/Kgwhen comparedwith control (vehicle).
4. Discussion
There is little information about the biological properties of
Xylopia laevigata. In fact, we did a search using Chemical
Abstracts, Biological Abstracts, Web of Science, and Sci-
enceDirect (updated to December 2013) and did not find
any article on the same pharmacological properties of this
species investigated in our work. We believe that it is the
first scientific report on the antioxidant, analgesic, and anti-
inflammatory profiles of the X. laevigata species and which
sought tomap the CNS areas involved in analgesic profile. So,
the aim of the study was to evaluate the antioxidant, antinoci-
ceptive, and anti-inflammatory potential of the essential
oil from the leaves of X. laevigata (EOX) in experimental
protocols.
Antioxidants comprise a broad and heterogeneous family
of compounds that share the common task of interfering
with (stopping, retarding, or preventing) the oxidation (or
autoxidation) of an oxidizable substrate [25]. Numerous
physiological and biochemical processes in the human body
may produce oxygen-centered free radicals and other reactive
oxygen or nitrogen species as by-products [26]. Overpro-
duction of such radicals can cause oxidative damage to
biomolecules, eventually leading to many diseases, such as
atherosclerosis, cancer, diabetes, or inflammatory conditions
and pain [16, 27]. Recently, there has been growing interest
in research into the role of plant-derived antioxidants in food
and human health [28].
Initially, the capacity for scavenging free radicals was
evaluated for EOX through the DPPH test. This test is
a very convenient method for screening small antioxidant
molecules because the intensity of reaction can be analyzed
by simple spectrophotometric assay [13]. DPPH radical is
scavenged by antioxidants through the donation of hydrogen
to form the stable, reduced DPPH molecule. Thus, the
antioxidant radicals are stabilized through the formation of
nonradical products [29]. EOX produced a potent antioxi-
dant effect.
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Table 3: Effect of X. laevigata leaf essential oil (EOX) or morphine (MOR), in the absence and presence of naloxone (NAL), on writhing
induced by acetic acid and formalin-induced nociception tests in mice.
Treatment Dose (mg/kg) Writhing test Formalin test
Number of writhingsa 0–5mina 15–30mina
Vehicle — 38.0 ± 4.1 79.5 ± 5.6 105.1 ± 23.3
EOX 12.5 24.8 ± 6.2 48.2 ± 5.7b 41.5 ± 12.9c
EOX 25 8.7 ± 3.4c 36.3 ± 6.7c 31.7 ± 8.3c
EOX 50 3.1 ± 2.8c 30.3 ± 7.2c 13.8 ± 6.6c,e
MOR 5 1.9 ± 0.6c 12.4 ± 2.8c 5.8 ± 1.1c
EOX + NAL 50 + 1.5 21.5 ± 6.1b,d — —
MOR + NAL 5 + 1.5 34.8 ± 7.3 — —
𝑛 = 8, per group. aValues represent mean S.E.M. b𝑃 < 0.05 (one-way ANOVA and Tukey’s test), significantly different from control group. c𝑃 < 0.001 (one-
way ANOVA and Tukey’s test), significantly different from control group. d𝑃 < 0.01 (one-way ANOVA and Tukey’s test), significantly different from EOX
50mg/kg group. e𝑃 < 0.05 (one-way ANOVA and Tukey’s test), significantly different from EOX 25mg/kg group.
Table 4: Effect of X. laevigata leaf essential oil (EOX) or indomethacin (INDO) on carrageenan-induced leukocyte migration and
carrageenan-induced hindpaw edema in mice.
Treatment Dose (mg/kg)
Carrageenan-induced
leukocyte migration
(leukocytes ×106/mL)a
% inhibition
Carrageenan-induced
hindpaw edema volume
(mL)a
% inhibition
Vehicle — 48.3 ± 2.8 — 0.61 ± 0.14 —
EOX 12.5 32.1 ± 3.6b 33.5d 0.40 ± 0.11b 34.4d
EOX 25 30.7 ± 2.2b 36.4d 0.36 ± 0.09b 41.0d
EOX 50 27.8 ± 4.3c 42.4d 0.34 ± 0.11b 44.3d
INDO 10 19.7 ± 2.5c 59.2e 0.21 ± 0.08c 65.6e
𝑛 = 6, per group. aValues represent mean ± S.E.M. b𝑃 < 0.01 (one-way ANOVA and Tukey’s test), significantly different from control. c𝑃 < 0.001 (one-
way ANOVA and Tukey’s test), significantly different from control. d𝑃 < 0.01 (Fisher’s test), significantly different from control. e𝑃 < 0.001 (Fisher’s test),
significantly different from control.
Nitric oxide (NO) exerts important physiological effects,
such as vasoconstriction regulation andmodulation of proin-
flammatory processes [30]. Reaction between some ROS
(notably superoxide) and NO is generally fast and may result
in “cleaning” of NO in some cells, with consequent inhibition
of someNO-triggered biological effects [16, 30]. So, NO plays
an important role in various types of inflammatory disorders
and thus might be implicated in the antinociceptive and anti-
inflammatory actions shaped by EOX.
Lipid peroxidation has been described as the biological
damage caused by free radicals that are formed under
oxidative stress [31]. Several plants have been shown to inhibit
lipid peroxidation, asmeasured by TBARS results [28, 32, 33].
The lipids inmembrane are continuously subjected to oxidant
challenges. Oxidant-induced abstraction of a hydrogen atom
from an unsaturated fatty-acid chain of membrane lipids
initiates the process of lipid peroxidation, which propagates
as a chain reaction [32]. In the process, cyclic peroxides,
lipid peroxides, and cyclic end peroxides are generated,
which ultimately are fragmented into aldehydes such as
malondialdehyde [26]. This antioxidant profile can be useful
formanaging disorders, as inflammation and pain [16, 32, 34].
In evaluation of the antinociceptive effect using acetic
acid-induced abdominal constriction, EOX produced a sig-
nificant inhibition of the nociceptive behavior. This test is a
standard, simple, and sensitive test for measuring analgesia
induced by both opioids and peripherally acting analgesics
[35]. In the present study, our results suggest that EOX has a
central analgesic effect. To confirm such an effect, we tested
the blocking effect of naloxone, a specific antagonist of mor-
phinomimetic receptors, in the acetic acid test [36]. Naloxone
was not able to completely reverse the antinociceptive effect
of EOX but appears to partially reverse this effect, suggesting
a weak involvement of opioid receptors. According to Le
Bars et al. [21], in the acetic acid test, pain is elicited by
the injection of an irritant, such as acetic acid into the
peritoneal cavity, which produces episodes of characteristic
stretching (writhing) movements; those behavioral changes
are probably in relation to the inhibition in the peritoneal
fluid levels of prostaglandin and cytokines [21, 37]. Thus,
EOX may also participate in the inhibition of prostaglandin
synthesis, as nociceptive mechanisms involve the processing
or release of arachidonic acid metabolites via COX and
prostaglandin biosynthesis [16].
Acute administration of EOX, at all doses, caused pro-
nounced antinociception as evidenced by the decreased
nociceptive behavior in the first and second phases of the
formalin test. This test model is sensitive to various classes
of analgesic drugs [20] and is characterized by the first phase
(neurogenic), which is evoked by direct formalin stimulation
of the sensorial C-fibers followed by substance P release
[38], and the second phase (inflammatory) mainly due to a
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Figure 3: Immunofluorescence staining of nuclear c-Fos in the neurons of the olfactory bulb (a, d, g, and j), piriform cortex (b, e, h, and
k), and periaqueductal gray (c, f, i, and l) 90 minutes after X. laevigata leaf essential oil (EOX) intraperitoneal injection at doses of 0 (saline
control), 12.5, 25, and 50mg/Kg, respectively, on these three brain regions of the animals submitted to carrageenan hypernociception model.
subsequent inflammatory reaction in the peripheral tissue
mediated by the release of various inflammatory mediators
associated with the increased level of PG, induction of COX,
and release of nitric oxide (NO) [21]. As EOX reduced the
production of nitrite, showing it to have a potential role
as a NO scavenging agent, and as NO plays an important
role in various types of inflammatory processes, it is thus
possible that the reduction of NO is involved in a potential
antinociceptive action produced by EOX, mainly in the
second phase of the formalin test [39].
To investigate if treatments with EOX could influence the
motor activity of the animals and consequently impair the
assessment of the nociceptive behavior in the experimental
models, the motor activity of the animals was evaluated
on a rotarod apparatus [16]. Our results revealed that all
mice treated with EOX, at the doses evaluated, did not show
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Table 5: Brain areas activated by X. laevigata leaf essential oil (EOX) in mice.
Treatment Dose FOS positive cells
(mg/kg) Olfactory bulb Piriform cortex Periaqueductal gray
Vehicle — 3.5 ± 0.6 3.0 ± 1.4 4.2 ± 1.3
EOX 12.5 11.7 ± 2.6 8.0 ± 1.7 23.7 ± 5.2a
EOX 25 22.0 ± 5.4a 29.5 ± 3.6b 28.7 ± 1.1b
EOX 50 25.7 ± 6.4b 34.0 ± 9.4b 19.2 ± 3.6a
𝑛 = 4, per group; values represent mean ± S.E.M. a𝑃 < 0.01 or b𝑃 < 0.001 (one-way ANOVA and Tukey’s test), significantly different from vehicle-treated
mice.
any performance alteration during the rotarod test (data no
shown).
To demonstrate central action of EOX, c-Fos labeled
by immunofluorescence was performed showing activation
of olfactory bulb, piriform cortex, and periaqueductal gray
(PAG). As demonstrated in immunohistochemistry results,
the acute treatment with EOX stimulated the olfactory bulb,
piriform cortex, and PAG. The olfactory bulb and piriform
cortex receive information from such brain areas as the
amygdala and hippocampus and project their axons to
targets in the amygdala and hypothalamus, where they may
influence aggressive, mating, and painful behavior [40, 41].
Following the report of Reynolds [42], the PAG was rapidly
established as being important to descend inhibition of spinal
nociceptive processing and also as a site where opioids, when
microinjected directly into the PAG, replicated the inhibitory
effects of electrical stimulation [43]. It also became clear
that stimulation in widespread sites in the brain, including
the sensory cortex, thalamus, hypothalamus, midbrain, pons,
and spinal cord, similarly produced inhibitory effects on
spinal nociceptive processing. Additionally, stimulation of
PAG area can produce descending inhibitory of pain effects
[44]. Thus, our results allow us to suggest that the EOX may
be acting by modulation of the descending pain-inhibitory
mechanisms. Actually, recent studies have suggested that
essential oils and/or terpenes can produce effects on descend-
ing pain pathways, as PAG and nucleus raphe magnus areas
[45, 46].
To evaluate its anti-inflammatory profile we seek to test
EOX in different models. Carrageenan has been widely used
as a noxious agent able to induce experimental inflam-
mation for the screening of compounds possessing anti-
inflammatory activity [47]. This phlogistic agent, when
injected locally into a rodent paw, produces a severe inflam-
matory reaction, which is discernible within 30min [48].
As described by Bhandare et al. [47], the development of
edema induced by carrageenan is a biphasic event; the early
phase of the inflammation is due to the release of histamine,
serotonin, and similar substances; the later phase is associated
with the activation of kinin-like substances and the release of
prostaglandins, proteases, and lysosome [49]. EOX inhibited
hindpaw edema and showed considerable anti-inflammatory
activity. In addition, the antioxidant action of EOX observed
in the TBARS and NO assays suggests that this essential
oil may act as a protective agent against oxidative damage
to membrane polyunsaturated fatty acids (PUFAs), such as
arachidonic acid, which is a very important component in
the response to inflammation via the cyclooxygenase (COX)
pathway [30].
Thus, to confirm the probable anti-inflammatory profile
of EOX, the peritonitis induced by carrageenanwas observed.
Cell recruitment during inflammation depends on the
orchestrated release of localmediators that are responsible for
local vascular and tissue changes aswell as for the recruitment
of host defense cells [50]. The inflammation induced by
carrageenan involves cell migration, plasma exudation, and
production of mediators, such as nitric oxide, prostaglandin
E2, interleukin (IL)-1𝛽, IL-6, and tumor necrosis factor
(TNF)-𝛼 [44].These mediators are able to recruit leukocytes,
such as neutrophils, in several experimental models. EOX
inhibited leukocyte migration induced by i.p. injection of
carrageenan (in the peritonitis model) in a dose-dependent
manner. In addition, it is possible that EOX, rich in hydropho-
bic molecules, interacts strongly with specific types of lipids,
and in a lipid-rich system, such as in the TBARS assay, lipids
with lesser affinity to EOX compounds and/or hydrophilic
portions of amphipathic lipids are more susceptible to radical
attack, allowing the initiation of a lipoperoxidation chain
reaction [17], and these effects may be contributing to the
anti-inflammatory property of EOX.
Additionally, Martins et al. [51] suggest that the antiox-
idant and anti-inflammatory effects of the essential oil of
Garcinia brasiliensis may be related to the presence of 𝛾-
muurolene and 𝛿-cadinene, two terpenoids rich in our oil.
Unfortunately, we cannot isolate these terpenoids in EOX
to test them separately. Even so, it is possible that the
pharmacological properties, such as anti-inflammatory and
analgesic, of EOX are related to the presence of terpenoid
compounds [52–54].
5. Conclusions
For the first time in literature, our results support that the
EOX exhibits an antioxidant action preventing lipoperoxi-
dation, NO release, and significant anti-inflammatory and
antinociceptive activities in rodents. EOX probably exerts
its antinociceptive effect by central inhibitory mechanisms
(with partial involvement of the opioid system) and does not
produce changes in motor coordination.
The probable anti-inflammatory activity of EOXmay play
a role in interfering with prostaglandin synthesis and also
might involve redox-mediated mechanisms. Also, this study
demonstrated, for the first time, that EOXhas relevant central
antinociceptive property probably due to the involvement of
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descending modulation of pain on CNS, as PAG.The current
findings support its medicinal use in the folk medicine of the
Brazilian Northeast as an analgesic and anti-inflammatory
medicine.
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